Marsh & McLennan Reports Solid Q1 Adjusted Results Amidst $425M Litigation Charge
MRSH is trading near its 52-week low of $164.89 (7.3% above the low).
Summary
Marsh & McLennan reported solid Q1 2026 adjusted financial results, with 8% adjusted EPS growth, but GAAP earnings were reduced by a $425 million Greensill litigation charge.
Key Events · Earnings and Guidance · MRSH
-
Q1 2026 Financial Results
Consolidated revenue increased 8% to $7.6 billion, with underlying revenue growth of 4% compared to the first quarter of 2025.
-
Adjusted Earnings Growth
Adjusted operating income rose 8% to $2.4 billion, and adjusted earnings per share (EPS) increased 8% to $3.29.
-
Greensill Litigation Charge Impacts GAAP
GAAP operating income decreased 12% to $1.8 billion, and GAAP EPS fell to $2.36, primarily due to a $425 million charge related to the Greensill litigation.
-
Share Repurchases Continue
The company repurchased approximately 4.2 million shares of stock for $750 million in the first quarter of 2026, continuing its existing program.
Analysis · MRSH · Finance
This 8-K officially reports Marsh & McLennan's first-quarter 2026 financial results, detailing strong underlying performance alongside a significant one-time litigation charge. While adjusted revenue and EPS showed healthy growth, GAAP figures were negatively impacted by a $425 million charge related to Greensill litigation. The company also continued its share repurchase program, buying back $750 million in stock. Investors will weigh the underlying operational strength against the impact of the litigation and its potential future implications.
At the time of this filing, MRSH was trading at $177.00 on NYSE in the Finance sector, with a market capitalization of approximately $84.7B. The 52-week trading range was $164.89 to $239.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.